Literature DB >> 17886609

Peritoneal dialysis in congestive heart failure.

Abirami Krishnan1, Dimitrios G Oreopoulos.   

Abstract

Heart failure is a major and growing health problem. Major advances leading to newer therapies are being made in understanding the pathophysiology of heart failure as a chronic progressive disorder. Whatever the cause, all heart failure patients eventually progress to a refractory stage characterized by worsening renal function and resistance to diuretic therapy with attending severe edema. A logical treatment for this "cardiorenal syndrome" is the use of dialysis, which is efficient in treating both the hypervolemia and azotemia of refractory heart failure. Although all modalities of dialysis have been tried, peritoneal dialysis (PD) is the simplest choice and offers several advantages. It is an already-established long-term home-based therapy and does not require complex machinery or hospital resources. It is associated with preservation of residual renal function, gentle continuous ultrafiltration, hemodynamic stability, better middle-molecule clearance, sodium sieving with maintenance of normonatremia and perhaps less inflammation than hemodialysis is, especially with newer PD solutions. In the present paper, we discuss the potential advantages of PD in the treatment of heart failure, review the available literature, and lay some foundations for future research.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17886609

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  8 in total

1.  Peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics.

Authors:  Cécile Courivaud; Amir Kazory; Thomas Crépin; Raymond Azar; Catherine Bresson-Vautrin; Jean-Marc Chalopin; Didier Ducloux
Journal:  Perit Dial Int       Date:  2013-09-01       Impact factor: 1.756

2.  Use of peritoneal ultrafiltration in the elderly refractory congestive heart failure patients.

Authors:  Çağlar Ruhi; Hüseyin Koçak; Asuman Yavuz; Gültekin Süleymanlar; F Fevzi Ersoy
Journal:  Int Urol Nephrol       Date:  2012-03-03       Impact factor: 2.370

Review 3.  Cardiorenal syndrome: pathophysiology and potential targets for clinical management.

Authors:  Parta Hatamizadeh; Gregg C Fonarow; Matthew J Budoff; Sirous Darabian; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2012-12-18       Impact factor: 28.314

4.  Prognosis in patients with congestive heart failure and subacute renal failure treated with hemodialysis.

Authors:  Gregor Lindner; Edith Doberer; Andreas Vychytil; Gürkan Sengölge; Samo Wakounig; Deddo Moertl; Walter H Hörl; Wilfred Druml
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

5.  Prolonged use of the tyrosine kinase inhibitor in a peritoneal dialysis patient with metastatic renal cell carcinoma: possible beneficial effects on peritoneal membrane and peritonitis rates.

Authors:  Shruti N Tapiawala; Joanne M Bargman; Dimitrios G Oreopoulos; Martin Simons
Journal:  Int Urol Nephrol       Date:  2009-03-03       Impact factor: 2.370

6.  Renal replacement therapy in congestive heart failure requiring left ventricular assist device augmentation.

Authors:  Bernadette A Thomas; Christine M Logar; Arthur E Anderson
Journal:  Perit Dial Int       Date:  2012 Jul-Aug       Impact factor: 1.756

Review 7.  Extracorporeal versus peritoneal ultrafiltration in diuretic-resistant congestive heart failure--a review.

Authors:  Zofia Wańkowicz; Agnieszka Próchnicka; Anna Olszowska; Daniel Baczyński; Paweł Krzesiński; Mirosław Dziuk
Journal:  Med Sci Monit       Date:  2011-12

8.  Ultrafiltration by Peritoneal Route in Refractory Chronic Congestive Cardiac Failure.

Authors:  S Hedau; R Chakravarthi; V Reddy
Journal:  Indian J Nephrol       Date:  2018 Jul-Aug
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.